HK44495A - Process for reducing the crystal size of ondansetron hydrochloride dihydrate - Google Patents

Process for reducing the crystal size of ondansetron hydrochloride dihydrate

Info

Publication number
HK44495A
HK44495A HK44495A HK44495A HK44495A HK 44495 A HK44495 A HK 44495A HK 44495 A HK44495 A HK 44495A HK 44495 A HK44495 A HK 44495A HK 44495 A HK44495 A HK 44495A
Authority
HK
Hong Kong
Prior art keywords
reducing
hydrochloride dihydrate
ondansetron hydrochloride
crystal size
size
Prior art date
Application number
HK44495A
Inventor
David Trevor Collin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10659180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK44495(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of HK44495A publication Critical patent/HK44495A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Glass Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to a process for reducing the crystal size of ondansetron hydrochloride dihydrate produced by crystallisation from solvent to a size which is suitable for effective distribution in a tablet blend, in particular 100% less that 250 mu m. The ondansetron hydrochloride dihydrate is desolvated by drying at elevated temperature and reduced or atmospheric pressure and is then rehydrated.
HK44495A 1989-06-28 1995-03-23 Process for reducing the crystal size of ondansetron hydrochloride dihydrate HK44495A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898914804A GB8914804D0 (en) 1989-06-28 1989-06-28 Process

Publications (1)

Publication Number Publication Date
HK44495A true HK44495A (en) 1995-03-31

Family

ID=10659180

Family Applications (1)

Application Number Title Priority Date Filing Date
HK44495A HK44495A (en) 1989-06-28 1995-03-23 Process for reducing the crystal size of ondansetron hydrochloride dihydrate

Country Status (20)

Country Link
US (1) US5622720A (en)
EP (1) EP0415522B1 (en)
JP (1) JP3093242B2 (en)
KR (1) KR0182789B1 (en)
AT (1) ATE110380T1 (en)
AU (1) AU637110B2 (en)
CA (1) CA2019944C (en)
DE (1) DE69011786T2 (en)
DK (1) DK0415522T3 (en)
ES (1) ES2060045T3 (en)
GB (1) GB8914804D0 (en)
HK (1) HK44495A (en)
HU (1) HU208009B (en)
IE (1) IE64715B1 (en)
IL (1) IL94888A (en)
NZ (1) NZ234267A (en)
RU (1) RU2002745C1 (en)
SA (1) SA90110025B1 (en)
UA (1) UA18249A (en)
ZA (1) ZA905002B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
EP1465901A4 (en) * 2002-02-19 2006-02-01 Teva Pharma Processes for desolvating solvates of atorvastatin hemi-calcium and atorvastatin hemi-calcium essentially free of organic solvent
AR039163A1 (en) 2002-03-28 2005-02-09 Synthon Bv VENLAFAXINE BESYLATE
JP2005529142A (en) 2002-04-29 2005-09-29 テバ ジョジセルジャール レースベニュタールシャシャーグ Process for producing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl) methyl] -4H-carbazol-4-one
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
WO2004045615A1 (en) * 2002-11-15 2004-06-03 Helsinn Healthcare Sa Palonosetron for the treatment of chemotherapy-induced emesis
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
US7288660B2 (en) 2004-05-07 2007-10-30 Taro Pharmaceutical Industries Limited Process for preparing ondansetron hydrochloride dihydrate having a defined particle size
ZA200707469B (en) * 2005-02-23 2008-11-26 Teva Pharma Rasagiline formulations of improved content uniformity
NZ560660A (en) * 2005-02-23 2010-11-26 Teva Pharma Rasagiline ( R(+)-N-propargyl-1-aminodan ) formulations of improved content uniformity
AU2007308378B2 (en) * 2006-10-24 2013-02-21 Helsinn Healthcare S.A. Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
FR2561244B1 (en) * 1984-01-25 1988-03-04 Glaxo Group Ltd TETRAHYDROCARBAZOLONE HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
US4845115A (en) * 1986-12-17 1989-07-04 Glaxo Group Limited Method of medical treatment
DK185489A (en) * 1988-04-22 1989-10-23 Duphar Int Res IMIDAZOLYLMETHYL-CYCLOALKANOEBAA INDOLONES, THEIR PREPARATION AND USE
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron

Also Published As

Publication number Publication date
IL94888A0 (en) 1991-04-15
IE64715B1 (en) 1995-08-23
SA90110025B1 (en) 2001-03-24
ES2060045T3 (en) 1994-11-16
ATE110380T1 (en) 1994-09-15
IL94888A (en) 1995-03-15
GB8914804D0 (en) 1989-08-16
ZA905002B (en) 1991-12-24
EP0415522A1 (en) 1991-03-06
UA18249A (en) 1997-12-25
JP3093242B2 (en) 2000-10-03
JPH0395178A (en) 1991-04-19
NZ234267A (en) 1992-11-25
DE69011786D1 (en) 1994-09-29
CA2019944C (en) 2000-05-09
DK0415522T3 (en) 1994-09-19
DE69011786T2 (en) 1994-12-15
HU208009B (en) 1993-07-28
HUT54140A (en) 1991-01-28
US5622720A (en) 1997-04-22
EP0415522B1 (en) 1994-08-24
HU904015D0 (en) 1990-12-28
RU2002745C1 (en) 1993-11-15
IE902333L (en) 1990-12-28
AU637110B2 (en) 1993-05-20
AU5787490A (en) 1991-01-03
IE902333A1 (en) 1991-01-16
CA2019944A1 (en) 1990-12-28
KR910000709A (en) 1991-01-30
KR0182789B1 (en) 1999-10-15

Similar Documents

Publication Publication Date Title
GB8914804D0 (en) Process
ES8300758A1 (en) Novel substituted pyrazinyl-1,2,4-oxadiazol-5-ones, a process for preparing same and a pharmaceutical composition containing same.
CS38989A2 (en) Method of phenoxyacetamidoderivative production
DE3072012D1 (en) Process for producing semiconductor devices, devices produced by the process, and circuits and articles including such devices
EP0455582A3 (en) Water-settable compositions, their use and process for the production of articles from such compositions
EP0312899A3 (en) Stabilisation of colour
HU9403618D0 (en) Process and facility for dryling and/or baking raw bricks
ZA922504B (en) Novel 2-spirocyclopropyl 4-acylcephems and processes for the preparation thereof
AU540927B2 (en) Process for the obtention of carbohydrates, derived from vegetal raw material and industrial process for its derivatives
JPS525700A (en) The process for production of silicon nitride
ZA919050B (en) Process for the production of 4,5,6,7-tetrahydro-imidazo-(4,5,ljk)(1,4)-benzidiazepine-2-(1h)-thiones as well as intermediate products
DE3165294D1 (en) Process for preparing 2,5-dialkyl-4-hydroxy-3(2h)-furanones and 4-alkenyl-dihydro-3(2h) furanones obtained as intermediate products
JPS5221995A (en) Packaging method for gas kettles or the like
JPS5216779A (en) Total weight control system of conveyed articles
JPS522961A (en) Articles transfer conveyor
JPS51122274A (en) Connecting apparatus for conveyor
JPS5293787A (en) Novel process for preparation of cephem derivatives
JPS51120302A (en) Process for controlling turbine
JPS5225388A (en) Apparatus for changing the direction of goods being conveyed
MY8600520A (en) N-aryl-n (1,4,5,6-tetrahydropyrimidin-2-yl) or (4,5,6,7-tetrahydro-1-h-1,3-diazepin-2-yl) ureas for intestinal disorders and as antihypertensives
JPS5240287A (en) Sequence controller
IE900192L (en) Process and intermediates for isopropyl¹3s-amino-2r-hydroxy-alkanoates
JPS5232898A (en) Process for production of cubic boron nitride
SG169394G (en) Process for reducing the crystal size of ondansetron hydrochloride dihydrate
HU910234D0 (en) Process for decreasing the microbial impurity of plant parts

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20100626